A 53-kDa cellular phosphoprotein known as p53 has been associated with malignant transformation in several model systems (1) (2) (3) . Elevated levels of p53 are detected in transformed primate and rodent cell lines. The protein is detectable in many actively proliferating, nontransformed cells but is undetectable or present at low levels in resting cells (4) . The synthesis of p53 increases in resting cells after stimulation with mitogen (5) , and stimulated cells can be blocked from entering S phase by microinjections of p53-specific antibody (6) . Changes in levels and synthesis of p53 are often concomitant with malignant transformation (1, 7, 8) . Protein encoded by the p53 gene can complement activated ras genes in in vitro transformation of primary rodent cell cultures (9, 10) and can prolong the lifespan of such cells (11) . These observations suggest a direct role for p53 in oncogenesis of at least some cell types and are further supported by observations on the Abelson virus-transformed murine cell line L12, which does not normally express p53 because its gene has been inactivated by insertion of a retrovirus-like sequence within its first intron. L12 cells do not induce progressively growing tumors in syngeneic mice, but, when a functional p53 gene is introduced into these cells, transformed L12 cells do induce tumors (12) .
Because of these associations of the p53 gene with neoplasia in model systems, we undertook a systematic investigation of this gene in fresh human tumors. We found that alterations ofthis gene were present in three of six human osteogenic sarcomas in vivo but in no other tumor studied. Two of the fresh tumors expressed an immunoreactive protein of53 kDa. Alterations of the p53 gene were also found in three human osteogenic sarcoma cell lines.
MATERIALS AND METHODS
Solid tumors and accompanying normal tissues were obtained at surgery, and leukemic cells were obtained from peripheral blood. Samples were obtained before chemotherapy or radiotherapy and stored at -70°C. Eighty-five percent of adenocarcinomas and squamous carcinomas were primary tumors, and 15% were metastatic. All other malignancies were primary tumors or leukemias.
Genomic DNA was extracted by described methods (13) using cesium chloride density gradient ultracentrifugation and was digested with appropriate restriction endonucleases according to the directions of the supplier. The resulting fragments were separated by electrophoresis on 0.8% agarose gels, transferred to coated nylon filters, and hybridized to nick-translated 32P-labeled probes as described (13) . Autoradiographs of the hybridized filters were made with Kodak intensifying screens. Probes included (i) pR4-2, a cDNA probe encompassing exons 2-10 and parts of exons 1 and 11 (14) , generously provided by E. Harlow (Fig. 1) . Abnormalities of the p53 gene restriction pattern were detected in 3 osteogenic sarcomas (Fig. 2 ) but in no other tumor DNA. Analyses with the additional restriction enzymes BamHI, HindIII, and Bgl II and additional p53 probes limited to the 5' portion and the midportion of the gene were used to define the likely sites of the rearrangements in these tumors.
Using the pR4-2 probe, osteogenic sarcoma 1 (OS1) had normal 15-and 3.7-kb EcoRI bands as well as a larger-thannormal EcoRI band ( Fig. 2A , lane c). OS1 DNA had the predominant 7.8-kb BamHI fragment (Fig. 2B , lane c) and a normal HindIII restriction pattern (Fig. 2C , lane c), but had a Bgl II fragment smaller than the normal 12-kb size (Fig. 2D , lane c). Additional tests with the 5' probe (pBT53) and EcoRI digestion generated the normal 3.5-kb fragment suggesting that the region' encompassing the first exon was intact. This analysis indicated that the p53 gene in this tumor was rearranged within the first intron and that the restriction fragments containing the coding sequences were apparently intact. The rearrangement was homozygous since no normal Bgl II 12-kb band was detected. Normal tissue from this patient contained a p53 gene that had the germ-line configuration (data not shown), indicating that the alteration of this gene in the sarcoma was an acquired abnormality and not a polymorphism.
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Expression of p53. Fresh tumor tissues were not available for mRNA analyses; however, sufficient tissue was available from tumors OS1 and OS2 for immunologic analysis of p53 levels using the monoclonal antibody PAb122 (16) . As seen in Fig. 5 , OSi and OS2 had distinct p53 bands that were as intense as bands from the actively proliferating B-lymphocyte cell line BV173 and that were more intense than bands from two osteogenic sarcomas and two colon cancers without detectably rearranged p53 genes. The levels of p53 in the fresh tumors were not as great as levels in the two related cell lines HOS and MNNG/HOS derived from an osteogenic sarcoma. Lines MG-63 (osteogenic sarcoma) and COLO 667 (a line derived from a Hodgkin tumor) had rearranged p53 genes without evidence of expression in vitro either at the level of mRNA (data not shown) or protein (Fig. 5) . We could not detect p53 protein in the osteogenic sarcomas Saos-2 and U-20S using immunoblots (data not shown).
DISCUSSION
Osteogenic sarcoma is a neoplasm of malignant osteoblasts. It is recognizable histologically by the capacity of neoplastic cells to synthesize osteoid. Like most other sarcomas it is thought to originate in cells arising from the embryonic mesoderm. It is the most common primary tumor of bone and occurs both in sporadic and familial forms. Clinically the (1987) tumor is characterized by occurrence in young people, aggressive growth, and frequent metastases to lung.
The human genome contains a single p53 gene containing 11 exons and spanning -20 kb (14) . The alterations of the p53 gene observed in osteogenic sarcoma tumors in vivo and in cell lines in vitro are summarized in Table 1 . Our analysis of osteogenic sarcoma tumors and cell lines indicates that rearrangements of the p53 gene occurred in the first intron in three tumors and one cell line. One cell line had lost all coding sequences other than those in the first exon.
The human osteogenic sarcoma cell lines have extensive chromosomal rearrangements rendering complex the interpretation of the rearrangements of the p53 gene on chromosome 17 (17) . U-20S varies from hypodiploid to near tetraploid with abnormalities including dicentrics, breaks, rings, and minute markers. Saos-2 varies from hyperdiploid to hypopentaploid with chromosome breaks, secondary constrictions, and double minutes. Karyotype analysis of the fresh tumors was not possible. The significance of frequent rearrangements of the p53 gene in osteogenic sarcomas in vivo (3 of 6 osteogenic sarcomas examined) contrasted with its rarity in other fresh human tumors (0 of 126 tumors) is uncertain. Two of the sarcomas with rearrangements in the first intron synthesized immunologically detectable p53. This protein was not detected in four other tumors lacking p53 rearrangements.
p53 levels are elevated in many murine tumors and tumor cell lines. The elevated levels may result both from increased mRNA synthesis and from stabilization of a protein with a very short half-life (18) (19) (20) . Interaction with the large tumor antigen of simian virus 40 or the adenovirus Elb 58-kDa protein can also stabilize p53 and increase the concentration from a few hundred molecules to 10,000 molecules per cell (21, 22) . It is not certain, therefore, whether the relatively high levels of p53 protein observed in two osteogenic sarcomas (OS1 and OS2) in vivo reflected rearrangements of the p53 gene or post-transcriptional modifications. The elevation of p53 levels in these tumors probably did not simply reflect higher levels of cell proliferation since histologic analysis did not reveal an unusually high frequency of mitoses when compared to the osteogenic sarcomas without detectable p53 rearrangement. The possibility that a rearrangement involving the first exon of p53 in osteogenic sarcomas alters transcriptional activity of the gene must be considered, as is the case with some gene rearrangements in Burkitt lymphomas involving the first noncoding exon of MYC (23, 24) . Interestingly, the first exon of the p53 gene is also noncoding (10) but shows evolutionary conservation (25) . Furthermore, mutations produced in 5'-coding sequences of the murine p53 gene give rise to stable protein products and can extend the life span of recipient cells (11) .
